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population to which the results will later 
be applied. In the present study, neither 
physicians nor patients were randomly 
selected. The convenience sample of 15 
volunteer patients, whose characteristics 
(age, sex, subtypes of pemphigus, time in 
the course of the disease, i.e., before or 
after treatment) are not described, can-
not be assumed to represent patients 
who may be included in future trials. 
The PV-to-PF ratio was not provided—
PV accounts for about two-thirds of all 
pemphigus cases and PF for about 20%. 
These points are important, because 
the clinical characteristics included in 
the scale (mucous membrane involve-
ment), prognosis, and therapeutics dif-
fer between PV and PF, and it is impos-
sible to estimate to which population the 
results could be extrapolated.
Overall, validated outcome mea-
sures are essential for optimal patient 
care. Therefore, the successive research 
work of this International Pemphigus 
Committee is of major importance, and 
this study on outcome instruments for 
pemphigus is a first approach. The assess-
ment of larger, well-defined populations 
with a formal evaluation, including the 
usual successive methodological steps, is 
needed before the PDAI should be used 
as a research instrument.
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Protein Kinase cα Puts the Handcuffs 
on epidermal Keratinocyte Proliferation
Wendy B. Bollag1,2
As the predominant cellular receptor for phorbol esters, protein kinase c (PKc) is 
assumed to play a role in epidermal carcinogenesis. nevertheless, determining its 
exact role in keratinocytes has been difficult because of the existence of multiple 
PKc isoforms and the inherent weaknesses in methodologies used to investigate 
their function. In this issue, Jerome-Morais et al. describe their use of multiple in 
vitro, in situ, overexpression, and knockdown approaches to demonstrate that 
PKcα induces keratinocyte growth arrest.
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The ability of phorbol esters to promote 
tumor formation in mouse epidermis 
preinitiated with a carcinogen led to 
the idea that the phorbol ester target 
in skin must be involved in epidermal 
tumorigenesis. Thus, the identification 
of protein kinase C (PKC) as the primary 
cellular target of phorbol esters suggested 
an important role for PKC in epidermal 
tumor formation, as well as for the biol-
ogy of the keratinocyte, the predominant 
cell in the epidermis (reviewed in Bollag 
and Bollag, 2001). However, despite an 
abundance of studies investigating the 
role of this enzyme in the epidermis, 
both in vitro and in vivo, the exact role of 
PKC in keratinocyte function and epider-
mal tumorigenesis remains unclear.
This imperfect knowledge about the 
role played by PKC in the epidermis is 
likely due in large part to the existence of 
multiple PKC family members, each with 
disparate mechanisms of activation and 
different function (reviewed in Bollag and 
Bollag, 2001). Thus, conventional PKC 
isoenzymes (PKCα, -βI, -βII, and -γ) are 
phospholipid dependent, diacyl glycerol 
activated, and calcium sensitive, where-
as the novel PKC isoforms (PKCδ, -ε, 
-η, and -θ) also require phospholipids 
and are activated by diacylglycerol, but 
they are insensitive to calcium. Atypical 
PKCs (PKCζ and -λ/ι), on the other hand, 
require neither diacylglycerol nor cal-
cium (Figure 1). Because phorbol esters 
can substitute for naturally occurring 
diacylglycerol in activating conven-
tional and novel PKC isoenzymes, the 
ability of phorbol esters to promote epi-
dermal tumor formation indicates the 
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importance of these targets in keratino-
cyte biology. However, because phor-
bol esters can activate all eight classic 
and novel PKC isoforms, the specific 
isoform(s) involved in tumor promotion 
remains uncertain.
Another difficulty in achieving a com-
plete understanding of the role of PKC 
isoforms in epidermal tumorigenesis is 
related to the relative nonspecificity of 
the phorbol ester tumor promoters them-
selves. Thus, in addition to stimulating 
the activity of all of the conventional 
and novel PKC isoenzymes, phorbol 
esters can also activate some non-PKC 
targets, including Ras-GRP1 (a guanine 
nucleotide exchange factor for Ras), 
chimaerins (Rac GTPase-activating pro-
teins), Munc13s (involved in synaptic 
vesicle priming), diacylglycerol kinase-γ 
(a diacylglycerol-metabolizing enzyme), 
and protein kinase D (PKD; reviewed in 
Brose and Rosenmund, 2002). (Although 
PKD has also been described as PKCµ, 
this enzyme and related PKD2 and 3 are 
now classified as members of a kinase 
family separate from the PKCs (Brose 
and Rosenmund, 2002).) In addition, 
phorbol esters can induce not only the 
activation of PKC but also the proteolytic 
degradation (downregulation) of many 
of the isoforms. Therefore, it is difficult to 
determine which of phorbol esters’ PKC 
or non-PKC targets underlies tumor pro-
motion and whether the response is the 
result of activation or downregulation of 
a particular (or several) PKC isozyme(s).
Our knowledge about the role of the 
PKC isoforms in the epidermis is also 
complicated by the various approaches, 
with their attendant advantages and dis-
advantages, used to study their function. 
Many of the PKC isoenzymes have 
been studied in vitro, using both over-
expression and knockdown; similarly, 
genetically engineered mice both over-
expressing and lacking the genes for 
some of the isoforms have been gener-
ated. Overexpression studies have the 
potential difficulty that the overexpressed 
protein, in vitro or in vivo, may interact 
with proteins or substrates and/or local-
ize to regions of the cells not usually 
accessed by the endogenous protein. On 
the other hand, most knockdown strate-
gies have the potential for artifacts, and 
knockout mice can have alterations in 
other pathways to compensate for the 
loss of the deleted gene during develop-
ment. In addition, possible cell autono-
mous versus cell microenvironmental 
effects may exist in vivo (see below). All 
of these issues may complicate inter-
pretation of the role of a particular PKC 
isoenzyme in epidermal function and 
tumorigenesis and necessitate careful 
studies using multiple approaches, such 
as the work reported by Jerome-Morais 
et al. in this issue.
Of the conventional PKC isoforms 
expressed in the epidermis, PKCα is the 
most abundant. (Although some inves-
tigators have reported that PKCα is the 
only conventional isoenzyme found 
in epidermal keratinocytes, recent 
data suggest that PKCβII may also be 
expressed in keratinocytes (our unpub-
lished results and Hara et al., 2005).) In 
vitro, adenovirus-mediated overexpres-
sion of the PKCα isoform, as well as 
PKCδ, -ε, and -η, induces the expres-
sion of involucrin (reviewed in Bollag 
and Bollag, 2001), as well as keratins 
1 and 10, loricrin, and filaggrin (Seo et 
al., 2004), although there is no effect on 
growth arrest or transglutaminase activ-
ity (Ohba et al., 1998). Furthermore, 
over expression of a dominant negative 
mutant or antisense ablation of PKCα 
inhibits the expression of multiple differ-
entiation markers in response to elevated 
extracellular calcium levels, a known 
keratinocyte-differentiating agent (Seo 
et al., 2004, and reviewed in Bollag and 
Bollag, 2001). Together, these results 
indicate a role for PKCα in promoting 
keratinocyte differentiation.
This interpretation has been largely 
confirmed, although it is somewhat dis-
puted by data obtained in vivo. In trans-
genic mice engineered to overexpress 
PKCα in the skin, no effect on carcinogen-
initiated, phorbol ester–promoted tumori-
genesis is observed despite a striking effect 
of this overexpression on inflammation in 
the skin (Cataisson et al., 2005; Jansen et 
al., 2001; Wang et al., 1999). On the other 
hand, in PKCα knockout mice Hara et al. 
(2005) observed an impairment of epi-
dermal hyperplasia in response to tumor 
promoter application, but an increased 
sensitivity to tumor formation. Changes 
in tumor formation, however, may not 
be related only to effects in keratinocytes. 
It is thought that cell types in addition to 
keratinocytes are involved in epidermal 
tumorigenesis; therefore, total ablation 
of a gene in all cell types can compli-
cate interpretation of the results obtained 
because it becomes unclear whether any 
figure 1. Protein kinase c isoenzyme structure. PKC isoforms can be divided into three subtypes: 
the conventional, or classic, PKCs (cPKCs); the novel PKCs (nPKCs); and the atypical PKCs (aPKCs). The 
cPKC and nPKC isoenzymes possess the following domains: the pseudosubstrate (PS) domain, which 
in the unstimulated state interacts with the substrate binding domain and inhibits PKC activity; the two 
C1 domains that bind diacylglycerol or phorbol ester; the C2 domain that binds calcium (a C2-like 
(C2L) domain found in nPKCs does not bind calcium but mediates protein–protein interactions); and the 
catalytic domain of the enzyme (formed by C3 and C4). On the other hand, aPKCs possess only one C1 
domain and thus do not bind diacylglycerol; likewise, they lack a C2 domain. Protein kinase D (PKD), 
originally described as PKCµ but now placed in a separate kinase family, possesses two C1 domains, 
allowing diacylglycerol/phorbol ester binding, as well as the catalytic domain, which has greater 
homology to calcium/calmodulin-dependent protein kinases than to PKCs. In addition, PKD possesses 
two domains not observed in PKCs: an N-terminal hydrophobic domain (NTHD) of unknown function 
and a pleckstrin homology (PH) domain involved in protein–protein interactions.
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alteration in tumor formation is caused 
by a lack of the gene/protein in the epi-
dermal keratinocytes themselves (i.e., cell 
autonomous) or its absence in cells that 
communicate with the keratinocytes dur-
ing tumorigenesis (e.g., in dermal fibro-
blasts and infiltrating immune cells and 
their ability to generate a particular micro-
environment).
As an example, in null mice lack-
ing phospholipase Cε, a resistance to 
tumori genesis in the two-stage chemical 
carcinogenesis protocol is observed; 
however, this resistance is the result of 
alterations not in the keratinocytes them-
selves but in the inflammatory response 
initiated by phorbol esters (Ikuta et al., 
2008). Thus, total ablation of PKCα may 
result in a different phenotype than might 
be observed in mice in which PKCα loss 
is restricted to epidermal keratinocytes. 
Furthermore, although mice have the 
advantage of being genetically tractable 
with skin that is a reasonable model for 
the human organ, there are some differ-
ences in the epidermis of the two spe-
cies, necessitating research strategies that 
are amenable to human keratinocytes 
as well in order to address these poten-
tial disparities. Thus, through a variety 
of approaches in vitro and in vivo, clues 
have been obtained concerning the role 
of PKCα in epidermal keratinocyte biol-
ogy. Nevertheless, additional studies are 
needed to further define the important 
function(s) of this enzyme.
In this issue, Jerome-Morais et al. use 
multiple approaches to dissect the role of 
PKCα in keratinocytes. First, the authors 
were able to demonstrate in human 
epidermis in situ that PKCα is local-
ized in the plasma membrane of cells 
of the first spinous layer. Because PKCα 
requires phospholipid for activation, 
membrane-located protein kinase is 
thought to represent activated enzyme. 
However, and perhaps more impor-
tant, they also used a carefully validated 
antibody that detects PKCα-mediated 
phosphorylation of PKCα substrates on 
serine and threonine residues to dem-
onstrate that this enzyme was indeed 
active in the spinous layer. In addition, 
using overexpression of a constitutively 
active PKCα, Jerome-Morais et al. (2009) 
showed that PKC activity results in kera-
tinocyte growth arrest, as monitored by 
decreases in cell number, colony-forming 
efficiency, and radiolabeled thymidine 
incorporation into DNA (a measure of 
DNA synthesis) and an increase in the 
percentage of cells in the G0/G1 phase of 
the cell cycle (with a concomitant reduc-
tion of the percentage in the S phase). 
These authors then utilized the converse 
approach, PKCα knockdown with RNA 
interference technology, as well as a 
three-dimensional organotypic culture 
system, to demonstrate that decreases in 
PKCα levels resulted in a thinner orga-
notypic raft epidermis despite an increase 
in proliferation in the culture. This appar-
ently paradoxical result is nevertheless 
consistent with the findings of Hara et 
al. (2005), in which mice lacking PKCα 
exhibited reduced epidermal thickness 
after wound healing but enhanced tum-
origenesis upon carcinogen initiation and 
tumor promotion. Together, the results 
suggest multiple roles of PKCα in epider-
mal keratinocytes: not only as a tumor-
suppressive, growth-inhibitory signal but 
also as a migration- and/or stratification-
inducing signal, as discussed in the arti-
cle by Jerome-Morais et al. It should be 
noted, however, that not all of the cellu-
lar functions of PKCα may require cata-
lytic activity. As an example, kinase-dead 
PKCα can activate phospholipase D (e.g., 
Oka et al., 2003); it will therefore be of 
interest to ascertain which of the defects 
observed with PKCα knockdown can be 
rescued by wild-type versus catalytically 
inactive mutant PKCα.
The complex regulation of the epi-
dermal keratinocyte program of self-
renewal, proliferation, and differentiation 
makes it difficult to decipher the signal-
ing pathways mediating these processes. 
However, because of the likely contri-
butions of alterations in these pathways 
to the etiology of skin diseases, includ-
ing tumorigenesis, studies to decode 
the secrets of these cells are impera-
tive. As exemplified in the report by 
Jerome-Morais et al., the use of two- and 
three-dimensional human keratinocyte 
cultures, as well as both overexpression 
and knockdown methodologies, repre-
sents a sound and multifaceted approach 
to investigating the complicated signaling 
pathways regulating epidermal structure 
and function.
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Multi-dimensional 
cultures and 
overexpression 
and knockdown 
methodologies are 
required to study 
epidermal signaling.
